Thousands Join Lundbeck and the Hereditary Disease Foundation to Build Hope for Huntington’s Disease

  Thousands Join Lundbeck and the Hereditary Disease Foundation to Build Hope
  for Huntington’s Disease

   Campaign supports families in Venezuela who made possible groundbreaking
                        Huntington’s disease research

Business Wire

DEERFIELD, Ill. -- November 14, 2012

Today, Lundbeck announced the results of its third annual Build Hope for HD
campaign, benefitting the Casa Hogar Amor y Fe (House of Love and Hope), a
unique clinic that provides care for people affected by Huntington’s disease
(HD). Build Hope for HD, which launched on August 1, 2012, consisted of an
online awareness campaign that included an opportunity to click, triggering a
donation on BuildHopeforHD.com. Participation from thousands in the HD
community and beyond helped spread awareness about this important cause, and
resulted in Lundbeck making a donation of $50,000 to the clinic. These funds
will allow the clinic to continue to provide treatment, food and medical care
to thousands of family members with HD who live along the shores of Lake
Maracaibo in Venezuela.

“The support from Lundbeck and the HD community allow the Casa Hogar to
continue to provide treatment and care to thousands of people affected by HD
living around Lake Maracaibo,” said Dr. Nancy Wexler, President of the
Hereditary Disease Foundation (HDF) and Higgins Professor of Neuropsychology,
Columbia University. “These families are living in extreme circumstances of
poverty and duress, and the support from Build Hope helps provide them with
basic medical necessities.”

Opened in 1999,^1 the clinic was built in gratitude to the families whose help
was critical to researchers who identified the HD gene in 1983 and isolated it
in 1993.^2,3 The clinic is now home to over 65 people and provides care and
food to many more from the surrounding community. For more than a decade, HDF
has continued to support the costs of medicine, supplies, salaries and other
expenses at this unique clinic.

This year marks Lundbeck’s third year of support for the clinic, which
supports a community that has played such a pivotal role in the scientific
understanding of Huntington’s disease. In total, the Build Hope campaigns have
resulted in $220,000 in donations from Lundbeck, and funds have been used to
renovate and update the clinic’s facilities, purchase new hospital equipment
and assist in the general day-to-day operations of the facility.

“We are inspired by the unwavering dedication of HDF and the Casa Hogar clinic
to bring urgently needed care and support to these families living with HD,”
said Staffan Schüberg, president of Lundbeck in the U.S. “We look forward to
continuing our support of important initiatives that assist the HD community.”

About Huntington’s Disease

Huntington’s disease is a hereditary neurodegenerative disease characterized
by a triad of progressive motor, cognitive and emotional symptoms.^4 These
symptoms vary from person to person. The survival time after the onset of
symptoms can range from 10 to 30 years^5 and currently there is no cure.^5 The
HD gene, whose mutation results in the disease, was localized in 1983 and
isolated in 1993.^2,3

About the Hereditary Disease Foundation

The Hereditary Disease Foundation aims to cure Huntington’s disease by
supporting research aimed at developing new treatments and cures. HDF was
started by Dr. Milton Wexler in 1968 when his wife was diagnosed with
Huntington's disease. The Foundation uses a variety of strategies – workshops,
grants, fellowships, and targeted research contracts – to solve the mysteries
of genetic disease and develop new treatments and cures. HDF initiated the
International-Venezuela Huntington’s Disease Collaborative Research Project
and played a key role in the discovery of the HD gene, which was localized in
1983 and isolated in 1993.^2,3 For more information, visit
www.hdfoundation.org.

About Lundbeck in the U.S.

Lundbeck in the U.S., headquartered in Deerfield, Illinois, is a wholly-owned
subsidiary of H. Lundbeck A/S in Denmark. Lundbeck is committed to
accelerating our work in central nervous system (CNS) disorders such as
Huntington’s disease, for which few, if any effective treatment options are
available. In 2010, Lundbeck initiated the HD Research Initiative to identify
and ultimately commercialize therapies that may slow or halt the progression
of the Huntington’s disease. This research is driven by collaborations with
academic institutions and companies with promising compounds in development.
For more information, visit www.lundbeckus.com.

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical
company committed to improving the quality of life for people suffering from
psychiatric and neurological disorders. For this purpose, Lundbeck is engaged
in the research, development, production, marketing and sale of
pharmaceuticals across the world. The company's products are targeted at
disorders such as depression and anxiety, schizophrenia, epilepsy,
Huntington's, Alzheimer's and Parkinson's diseases. Lundbeck was founded in
1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs
approximately 6,000 people worldwide. Lundbeck is one of the world's leading
pharmaceutical companies working with brain disorders. In 2011, the company's
revenue was DKK 16.0 billion (approximately EUR 2.2 billion or USD 3.0
billion). For more information, please visit www.lundbeck.com.

Sources

1. Glimm, Adele. “Timeline.” Gene Hunter: the Story of Neuropsychologist Nancy
Wexler. New York. Scholastic. 2005 pg 106-107.

2. Gusella J, Wexler N, Conneally PM, Naylor S, Anderson M, Tanzi R, Watkins
PC, Ottina K, Wallace M, Sakguchi A, Young AB, Shoulson I, Bonilla E, Martin
JB. A polymorphic DNA marker genetically linked to Huntington’s disease.
Nature 1983; 306:234-238.

3. Huntington’s Disease Collaborative Research Group. A novel gene containing
a trinucleotide repeat that is expanded and unstable on Huntington’s disease
chromosomes. Cell 1993; 72:971-983.

4. Marshall FJ, Clinical Features and Treatment of Huntington’s Disease.
Movement Disorders 2004; 1:589-596.

5. Huntington’s Disease. Mayo Clinic.
http://www.mayoclinic.com/health/huntingtons-disease/DS00401/METHOD=print.
Last accessed 11/12/12.

Contact:

Lundbeck
Katie White, 847-282-1929